Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
and Cancerlit were searched from 1988 to April 1999 using the terms 'prostatecancer', 'prostateneoplasm', 'brachytherapy', 'seed implant', 'interstitial radiotherapy', 'practice guideline', 'meta-analysis', 'randomized clinical trial' and 'clinical trial'. Studies reported as abstracts were excluded from the review. The web-based version of this review reported that it is currently being updated using the following searches: MEDLINE from April 1999 to May 2001; Cancerlit from April 1999 to March 2001 (...) Systematic overview of the evidence for brachytherapy in clinically localized prostatecancer Systematic overview of the evidence for brachytherapy in clinically localized prostatecancer Systematic overview of the evidence for brachytherapy in clinically localized prostatecancer Crook J, Lukka H, Klotz L, Bestic N, Johnston M Authors' objectives To examine the role of brachytherapy (permanent seed implantation) in treating clinically localised (T1 and T2) prostatecancer. Searching MEDLINE
prostatecancer. Searching MEDLINE and Cancerlit were searched from 1966 to 2000 using the combined subject headings of 'prostateneoplasms', 'radiotherapy', 'biochemical control' and 'dose'. In addition, the citation lists of relevant articles were examined, and relevant journals published in 2000 were manually reviewed. Study selection Study designs of evaluations included in the review There was no stated restriction on the study design. Of the included studies, 2 were randomised trials (...) studies used non-standard units when reporting the dose. RT was delivered using external beam irradiation (19 studies), low-dose brachytherapy (4 studies), or high-dose brachytherapy (1 study). Participants included in the review The participants were patients with diagnosed prostatecancer. Some trials selected the patients by the stage (B1, B2, C1, C2); others categorised the patients using a combination of risk factors (Gleason score and/or tumour stage and/or prostate-specific antigen). These were
Maximal androgen blockade for advanced prostatecancer. This systematic review assessed the effect of maximal androgen blockade (MAB) on survival when compared to castration (medical or surgical) alone for patients with advanced prostate cancer.Randomized controlled trials were searched in general and specialized databases (MEDLINE, EMBASE, Cancerlit, Cochrane Library, VA Cochrane ProstateDisease register) and by reviewing bibliographies.All published randomized trials were eligible (...) for inclusion provided they (1) randomized men with advanced prostatecancer to receive a non-steroidal anti-androgen (NSAA) medication in addition to castration (medical or surgical) or to castration alone, and (2) reported overall survival, progression-free survival, cancer-specific survival, and/or adverse events. Eligibility was assessed by two independent reviewers.Information on patients, interventions, and outcomes were extracted by two independent reviewers using a standardized form. The main
recurrence of prostatecancer, asymptomatic distant metastases, symptomatic distant metastases, and death. Patients experiencing severe side effects or disease progression were switched to a second-line therapy. Each cycle lasted one month and transition probability data were derived from the literature. Outcomes assessed in the review The outcomes assessed in the review were used as inputs in the model. These were the efficacy (base-case and meta-analysis estimates) and toxicity of antiandrogen (...) of the strategies was clear. The six therapies were selected as they represented feasible interventions for patients with advance prostatecancer. However, it was unclear what the incremental cost-effective ratio of DES over no treatment was, although presumably the costs of treating disease not remedied by DES outweigh the cost of the DES itself. You should assess whether they represent widely used therapies in you own setting. Validity of estimate of measure of effectiveness The effectiveness analysis used
the available evidence on the effectiveness of brachytherapy for prostatecancer. Authors' conclusions The intermediate short-term results of brachytherapy (biochemical control levels and disease-free survival) for patients selected with a low risk of extraprostatic progression seem to be comparable to those of other therapeutic options, such as prostatectomy and external radiotherapy. There are no long-term data available, despite the fact that the results of a sample (n=77) followed up for 12 years were (...) of AST) with patients presenting prior irradiation of the pelvis, severe urethral obstruction and transurethral prostatic resection excluded. There is uncertainty with regard to localised prostatecancer (PC). Despite the fact that there is evidence that this type of tumour tends to present a slow progression, it is not clear whether the type of treatment will or will not help all men with PC to live longer. On the other hand it must be remembered that treatments can affect patient quality of life
Brachytherapy for the treatment of prostatecancer Brachytherapy for the treatment of prostatecancer Brachytherapy for the treatment of prostatecancer Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Brachytherapy for the treatment of prostatecancer. Canberra (...) : Medical Services Advisory Committee (MSAC) 2000: 45 Authors' objectives This report aims to assess the effectiveness of brachytherapy for prostatecancer. Authors' conclusions MSAC recommends that from the evidence pertaining to brachytherapy for the treatment of prostatecancer, interim public funding should be supported for patients with prostatecancer: - at clinical stages T1, T2a or T2b, with Gleason Scores of less than or equal to 6, prostate specific antigen (PSA) of less than or equal to 10 ng
. However, complications appear to be much less frequent with brachytherapy. In summary, this technology remains experimental until data are available to confirm its efficacy, particularly among men with localised, well-differentiated early stage prostatecancer with low pre-treatment PSA levels. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Brachytherapy; ProstaticNeoplasms; Radiotherapy Language Published English, French Country of organisation Canada Province or state Quebec (...) Brachytherapy and prostatecancer Brachytherapy and prostatecancer Brachytherapy and prostatecancer Conseil d'Evaluation des Technologies de la Sante du Quebec Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Conseil d'Evaluation des Technologies de la Sante du Quebec. Brachytherapy and prostatecancer. Montreal: Conseil d'Evaluation des
cyproterone acetate. MAB was given for 18, 24 or 36 months, or until disease progression. The AS comparators were: orchiectomy; orchiectomy plus cyproterone for 14 days; leuprolide; leuprolide plus flutamide for 15 days; goserelin; buserelin; and buserelin plus cyproterone for 14 days. Participants included in the review Studies of men with advanced prostatecancer were eligible for inclusion. Men with metastatic (88%) and locally advanced (12%) cancer were included. The men's ages ranged from younger (...) was used to combine the studies by pooling the log rank statistic for mortality, and its variance, which were calculated for each trial. A meta-analysis stratified by years of follow-up, age, and stage of disease was also conducted. Survival curves were plotted to determine 5-year survival. All of the analyses were conducted by intention-to-treat and a 2-sided P-test was used to test for statistical significance. Deaths reported to arise from other causes (i.e. not prostatecancer) were analysed
Using the free-to-total prostate-specific antigen ratio to detect prostatecancer in men with nonspecific elevations of prostate-specific antigen levels Using the free-to-total prostate-specific antigen ratio to detect prostatecancer in men with nonspecific elevations of prostate-specific antigen levels Using the free-to-total prostate-specific antigen ratio to detect prostatecancer in men with nonspecific elevations of prostate-specific antigen levels Hoffman R M, Clanon D L, Littenberg B (...) , Frank J J, Peirce J C Authors' objectives To determine whether the free-to-total prostate-specific antigen (PSA) ratio improved the diagnostic accuracy of non-specific PSA results. Searching MEDLINE was searched from January 1986 to July 1997 for publications in the English language. The search used a combination of the MeSH terms 'prostate-specific antigen' and 'prostaticneoplasm' and then linked them with 'alpha-1-antichymotrypsin' or with 'free' or 'gamma-semiprotein'. The bibliographies
Contrasting costs of a prostatecancer educational program by income Contrasting costs of a prostatecancer educational program by income Contrasting costs of a prostatecancer educational program by income Weinrich S P, Weinrich M, Ellison G, Hudson J, Reeder G, Weissbecker I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two alternative educational interventions, oriented to inform the risks and benefits of prostatecancer screening. There were followed by screening, using a digital rectal examination (DRE) and/or drawing of blood for a prostate-specific antigen (PSA) test, and a biopsy for those men with abnormal results. The core of the educational interventions included a slide-tape presentation
of prostatecancer patients by on-demand contacts with a specialist nurse: a randomized study. Scandinavian Journal of Urology and Nephrology 2000; 34(1): 55-61 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Cost-Benefit Analysis; Disease Progression; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Nurse Clinicians /economics; Outcome and Process Assessment (Health Care); Patient Care Team /economics; Patient Satisfaction; ProstaticNeoplasms (...) population Men with newly diagnosed or previously known prostatecancer in any stage were eligible for the study but the disease must have been judged to be clinically stable with an expected survival of more than three months. The exclusion criteria were: patients considered for curative treatment; patients participating in a trial that stipulated a specific follow-up protocol; or patients with psychiatric disorders or those whose general condition had deteriorated. Setting The study setting
Prostatecancer staging: should MR imaging be used? A decision analytic approach Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
to lessen the risk of radiation-related effects in a randomised controlled trial of conformal versus conventional radiotherapy.We recruited men with prostatecancer for treatment with a standard dose of 64 Gy in daily 2 Gy fractions. The men were randomly assigned conformal or conventional radiotherapy treatment. The primary endpoint was the development of late radiation complications (> 3 months after treatment) measured with the Radiation Therapy and Oncology Group (RTOG) score. Indicators of disease (...) in local tumour control (conformal 78% [95% CI 66-86], conventional 83% [69-90]).Conformal techniques significantly lowered the risk of late radiation-induced proctitis after radiotherapy for prostatecancer. Widespread introduction of these radiotherapy treatment methods is appropriate. Our results are the basis for dose-escalation studies to improve local tumour control.
1999LancetControlled trial quality: predicted high
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostatecancer. Because the optimal timing of the institution of antiandrogen therapy for prostatecancer is controversial, we compared immediate and delayed treatment in patients who had minimal residual disease after radical prostatectomy.Ninety-eight men who underwent radical prostatectomy and pelvic lymphadenectomy and who were found to have nodal metastases (...) cancer in 3 men in the immediate-treatment group and in 16 men in the observation group (P<0.01). At the time of the last follow-up, 36 men in the immediate-treatment group (77 percent) and 9 men in the observation group (18 percent) were alive and had no evidence of recurrent disease, including undetectable serum prostate-specific antigen levels (P<0.001). In the observation group, the disease recurred in 42 men; 13 of the 36 who were treated had a complete response to local treatment or hormonal
in detecting metastatic prostatecancer. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). HTB-5. 1999 Authors' objectives To summarise the effectiveness and cost-effectiveness of In-111 Capromab Pendetide in detecting metastatic prostatecancer. Authors' conclusions Imaging with In-111 Capromab Pendetide provides an additional method for detection of metastatic disease in prostatecancer. As the images are difficult to interpret, it would be essential for clinicians to receive (...) Use of In-111 Capromab Pendetide in detecting metastatic prostatecancer Use of In-111 Capromab Pendetide in detecting metastatic prostatecancer Use of In-111 Capromab Pendetide in detecting metastatic prostatecancer Howell T, Hailey D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Howell T, Hailey D. Use of In-111 Capromab Pendetide
Brachytherapy for prostatecancer Brachytherapy for prostatecancer Brachytherapy for prostatecancer Wills F, Hailey D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wills F, Hailey D. Brachytherapy for prostatecancer. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). AHFMR HTA Report 17. 1999 Authors' objectives (...) This report aims to review the recent literature relating to the use of brachytherapy in the treatment of prostatecancer. Authors' conclusions Biochemical outcomes indicate that brachytherapy is a reasonable option for treatment of early prostatecancer in the short term, or as a boost to external beam radiation in more advanced stages. However, its potential for influencing overall outcomes, particularly long term morbidity and survival are unknown. Alternative or complementary treatments
cancer are the second leading causes of death and the most frequently diagnosed malignancies in Canadian women and men, respectively. Age, ethnicity, and family history are definite risk factors for breast and prostatecancer. Hereditary breast and prostatecancers have been associated with alterations in the expression of tumour suppressor genes and oncogenes. The majority of hereditary breast cancers can be attributed to germ-line mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 (...) mutations in BRCA1 and one founder mutation in BRCA2, appear in about one-third of the breast cancer patients of Ashkenazi Jewish descent. Protein expression of the oncogene Bcl-2 (B cell leukemia/lymphoma-2) and p53 have roles as independent prognostic markers for disease-free survival after radical treatment for prostatecancer. Predisposing mutations in the hereditary prostatecancer 1 gene (HPC1) are responsible for only a minority of familial prostatecancer cases and they are likely to be most
the quality of life. Due to the insufficiencies in the current level of knowledge on prostatecancer, we lack the fundamental scientific knowledge on which to base decisions regarding those medical inventions best suited to prevent, diagnose or treat this disease. Efforts should be taken to increase our understanding of the disease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Mass Screening; ProstaticNeoplasms Language Published Norwegian Country of organisation Norway English (...) Screening for prostatecancer, Norwegian review of international studies Screening for prostatecancer, Norwegian review of international studies Screening for prostatecancer, Norwegian review of international studies Norwegian Knowledge Centre for the Health Services Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Norwegian Knowledge
Prostatecancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostatecancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostatecancer screening: evidence synthesis and update (INAHTA Joint Project) Schersten T, Baile M A, Asua J, Jonsson E Citation Schersten T, Baile M A, Asua J, Jonsson E. Deteccion precoz del cancer de prostata (projecto (...) INAHTA). Prostatecancer screening: evidence synthesis and update (INAHTA Joint Project) Vitoria Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-99-03. 1999 Authors' objectives
To summarize scientific evidence regarding the effectiveness and cost-effectiveness of mass screening for prostatecancer.
Authors' conclusions Mass screening for prostatecancer is not recommended because of lack of evidence regarding the benefits and the considerable risks of adverse effects